The pharmaceutical company PJSC Kyiv Vitamin Plant (KVP) increased its net profit by 2.2 times in the first nine months of 2025 compared to the same period in 2024, to UAH 235.185 million.
According to the company’s disclosure to the National Securities and Stock Market Commission, net sales revenue for January-September 2025 increased by 2.5% to UAH 3.529 billion.
In January-September 2025, the company produced 35.770 million packages of medicines, for a total of UAH 4.268 576 billion at list prices.
The average selling price of one package of medicines produced by KVZ was UAH 133, the average cost of a package of KVZ dietary supplements was UAH 125, and medical products were UAH 263 per package.
In addition, the company reported that in the first nine months of 2025, KVZ exported products worth UAH 123.391 million, which is 3.5% of total sales. KVZ’s main export markets are Kazakhstan, Moldova, Latvia, Uzbekistan, and Israel.
The company plans to increase sales by 17.5% in 2025.
In addition, the company reported that total research and development expenses for the third quarter of 2025 amounted to UAH 5.246 million, which is almost twice as much as in the previous quarter.
The main distributors of KVZ products are BaDM LLC, Optima-Pharm, LTD, and VENTA. LTD.
The company reports that, based on the results of the first nine months of 2025, KVZ ranked fourth in the pharmaceutical market in terms of retail sales in monetary terms, with a market share of 3.29%.
As reported, KVZ increased its net profit by 8.74% compared to 2023, to UAH 156.84 million, and its revenue from sales of goods increased by 14.71% to UAH 4.944 billion in 2024.
KVZ is one of the ten largest pharmaceutical companies in Ukraine. The company’s product portfolio includes more than 100 medicines and 20 dietary supplements.
According to the Opendatabot system, the ultimate beneficiary of KVZ is Canadian citizen Maxim Martin.
